|
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
|
Mar 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).
|
Oct 2013
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: Contemporary review and how we treat
|
Jan 2016
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R
|
Sep 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
|
Jan 2019
|
Am J Hematol
|
aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
|
Jan 2018
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors
|
Jan 2015
|
Am J Hematol
|
aplastic anemia
|
|
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
